The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY® Endovascular Robotic Surgical System. Microbot Medical Inc. (NASDAQ: MBOT) is a clinical- stage medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body. Statements to future financial and/or operating results, f ...

The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY® Endovascular Robotic Surgical System. "We are very excited to have a hospital of the caliber of Baptist Hospital of Miami performing clinical cases. It is very encouraging to see the progress of our clinical study, as within a couple of weeks we now have two sites actively enrolling patients," commented Harel Gadot, CEO, President and Chairman of Microbot Medical. Baptist Hospital of Miami is ...

The clinical trial at BWH is led by Dr. Dmitry Rabkin, MD, PhD, Assistant Chief, Division of Angiography & Interventional Radiology, who also performed this first human case. The trial is part of the Investigational Device Exemption ("IDE") for LIBERTY®, and the Company expects its results will support the future submission to the FDA and subsequent commercialization. Microbot Medical Inc. (NASDAQ:MBOT) is a clinical- stage medical device company that specializes in transformational micro-robotic technologi ...

BRAINTREE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the completion of the first procedure in a patient utilizing its LIBERTY® Endovascular Robotic Surgical System. The procedure took place at Brigham and Women's Hospital (BWH), a leading academic medical center located in Boston, Massachusetts, as part of the Company's pivotal human clinical trial. About Microbot Medical Further information about Microbot Medical is available at http://www.microbotmedical ...

"We are pleased to work with Dr. Rabkin and the team at Brigham and Women's Hospital on this clinical study." commented Harel Gadot, CEO, President and Chairman of Microbot Medical. "We believe their commitment to research and the advancement of science make them an ideal clinical study site." Microbot Medical Inc. (NASDAQ:MBOT) is a clinical- stage medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasin ...

"We are pleased to work with Dr. Rabkin and the team at Brigham and Women's Hospital on this clinical study." commented Harel Gadot, CEO, President and Chairman of Microbot Medical. "We believe their commitment to research and the advancement of science make them an ideal clinical study site." About Microbot Medical The Investigational LIBERTY® Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cu ...

Core Viewpoint - Microbot Medical Inc. has successfully closed a registered direct offering and a concurrent private placement, raising approximately $2.35 million to support the development of its LIBERTY® Robotic System and other corporate purposes [1][3]. Group 1: Offering Details - The company sold 1,566,669 shares of common stock at a price of $1.50 per share [1]. - In addition, the company issued series F preferred investment options to purchase up to 3,133,338 shares of common stock, also at an exercise price of $1.50 per share, which are immediately exercisable for two years [1]. - H.C. Wainwright & Co. acted as the exclusive placement agent for these offerings [2]. Group 2: Use of Proceeds - The net proceeds from the offerings will be utilized for the continued development, commercialization, and regulatory activities of the LIBERTY® Robotic System [3]. - Additional applications derived from the company's existing intellectual property portfolio will also be developed, along with general working capital and corporate purposes [3]. Group 3: Company Overview - Microbot Medical Inc. is a pre-clinical medical device company focused on transformational micro-robotic technologies aimed at improving clinical outcomes and accessibility within the human body [7]. - The LIBERTY® Endovascular Robotic Surgical System is designed to enhance surgical robotics in endovascular procedures by reducing the need for large equipment and minimizing radiation exposure [8].

HINGHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,566,669 shares of the Company's common stock at a purchase price of $1.50 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series F preferred investment options. The series F preferred investment o ...

The study will be conducted in the U.S., and the Company has already signed a clinical trial service agreement with a leading academic medical center. The Company is also in the process of engaging additional leading centers to participate in the trial. BRAINTREE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces that it has received the U.S. Food and Drug Administration's ("FDA") approval ...

BRAINTREE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces that it has received the U.S. Food and Drug Administration's ("FDA") approval to proceed with its pivotal human clinical trial as part of its Investigational Device Exemption ("IDE") application for its LIBERTY® Endovascular Robotic Surgical System. The study will be conducted in the U.S., and the Company has already signed a cli ...